Volume 29, Number 4—April 2023
Dispatch
Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020‒2022
Table
Comparison of antibody test results in 2 field surveys for SARS-CoV-2, Verona, Italy, May 2020 and November 2021
Characteristic |
2021 |
|||
Negative, no. (%) |
Positive, no. (%) |
Total, no. (%) |
p value |
|
IgG against nucleocapsid | ||||
2020 | <0.0001 | |||
Negative, no. (%) | 720 (83.4) | 143 (16.6) | 863 (100.00) | |
Positive, no. (%) | 17 (50.0) | 17 (50.0) | 34 (100.0) | |
Total, no.(%) |
737 (82.2) |
160 (17.8) |
897 (100.0) |
|
IgG against spike protein | ||||
2020 | ||||
Negative, no. (%) | 65 (7.6) | 796 (92.4) | 861 (100.0) | |
Positive, no. (%) | 0 (0) | 35 (100.0) | 35 (100.0) | 0.170* |
Total, no. (%) | 65 (7.3) | 831 (92.7) | 896 (100.0) |
*By Fisher exact test.
1These first authors contributed equally to this article.
2These senior authors contributed equally to this article.
Page created: January 19, 2023
Page updated: March 21, 2023
Page reviewed: March 21, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.